---
input_text: 'Induced Liver Regeneration Enhances CRISPR/Cas9-Mediated Gene Repair
  in Tyrosinemia Type 1. The efficiency of gene repair by homologous recombination
  in the liver is enhanced by CRISP/Cas9 incision near the mutation. In this study,
  we explored interventions designed to further enhance in vivo hepatocyte gene repair
  in a model of hereditary tyrosinemia. A two-AAV system was employed: one virus carried
  a Staphylococcus pyogenes Cas9 (SpCas9) expression cassette and the other harbored
  a U6 promoter-driven sgRNA and a fragment of fumarylacetoacetate hydrolase (Fah)
  genomic DNA as the homologous recombination donor. In neonatal mice, a gene correction
  frequency of ~10.8% of hepatocytes was achieved. The efficiency in adult mice was
  significantly lower at ~1.6%. To determine whether hepatocyte replication could
  enhance the targeting frequency, cell division was induced with thyroid hormone
  T3. This more than doubled the gene correction efficiency to 3.5% (p < 0.005). To
  determine whether SpCas9 delivery was rate limiting, the gene repair AAV was administered
  to SpCas9 transgenic mice. However, this did not significantly enhance gene repair.
  Finally, we tested whether the Fanconi anemia (FA) DNA repair pathway was important
  in hepatocyte gene repair. Gene correction frequencies were significantly lower
  in neonatal mice lacking the FA complementation group A (Fanca) gene. Taken together,
  we conclude that pharmacological induction of hepatocyte replication along with
  manipulation of DNA repair pathways could be a useful strategy for enhancing in
  vivo gene correction.'
raw_completion_output: |-
  primary_disease: Tyrosinemia Type 1
  medical_actions: Pharmacological induction of hepatocyte replication; Manipulation of DNA repair pathways
  symptoms: None listed
  chemicals: Thyroid hormone T3; Staphylococcus pyogenes Cas9 (SpCas9)
  action_annotation_relationships: Pharmacological induction of hepatocyte replication (with Thyroid hormone T3) TREATS Tyrosinemia Type 1; Manipulation of DNA repair pathways TREATS Tyrosinemia Type 1
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Manipulation of DNA repair pathways TREATS Tyrosinemia Type 1

  ===

extracted_object:
  primary_disease: MONDO:0010161
  medical_actions:
    - Pharmacological induction of hepatocyte replication
    - Manipulation of DNA repair pathways
  symptoms:
    - None listed
  chemicals:
    - Thyroid hormone T3
    - Staphylococcus pyogenes Cas9 (SpCas9)
  action_annotation_relationships:
    - subject: Pharmacological induction of hepatocyte replication
      predicate: TREATS
      object: Tyrosinemia Type 1
      subject_qualifier: with
      subject_extension: Thyroid hormone T3
    - subject: Manipulation of DNA repair pathways
      predicate: TREATS
      object: Tyrosinemia Type 1
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
